Zealand Pharma

CompanyDenmarkFounded 1998

Zealand Pharma develops one asset, in phase 3 (petrelintide in cardiovascular disease). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and CALCR; based in Denmark, founded in 1998.

1
Asset
Furthest stage: Phase 3
Raised: US$1.1bn; 4
Trials: 6
Signals

Pipeline

1

petrelintide
Activates amylin receptors to increase satiety, reduce food intake, and regulate blood glucose.
Phase 3, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, cardiovascular disease, obesity or overweight

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms7
Trials7
Funding rounds and grants2
Signals7
Similar companies6

Papers

Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist
ADA Scientific Sessions 2025 abstract, 13 Jun 2025